/Companies

Alkermes

NASDAQ: ALKS

Founded 1987 · 2,446 employees on LinkedIn · 4 known investors

Find your way into Alkermes

Sign up to see every warm intro you have to Alkermes

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Alkermes team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders. The company leverages neuroscience expertise to create treatments for patients with complex conditions that are traditionally underserved.

Founders & leadership

RFRichard F. Pops
Richard F. PopsChairman of the Board, former CEO
JRJoshua Reed
Joshua ReedChief Financial Officer
BCBlair C. Jackson
Blair C. JacksonChief Executive OfficerBlair C. Jackson is President and CEO of Alkermes, a pharmaceutical company developing medicines for psychiatric and neurological disorders. Jackson has led cross-functional initiatives and strategic transitions throughout a career focused on operational rigor, organizational effectiveness, and integrating science with business strategy.
DJDavid J. Gaffin
David J. GaffinSenior Vice President, Chief Legal Officer and Chief Compliance Officer, Alkermes, Inc.
CCCraig C. Hopkinson
Craig C. HopkinsonExecutive Vice President, Research and Development and Chief Medical Officer
CT
C. Todd NicholsChief Commercial OfficerTodd Nichols is Senior Vice President and Chief Commercial Officer at Alkermes, where he oversees commercial strategy for psychiatric and neurological treatments. He has held leadership roles spanning marketing, sales, and general management across multiple therapeutic areas including psychiatry, neurology, rare disease, and specialty care.

Investors · 4

Founder mafia

3 people who came through Alkermes went on to found or lead other companies.

Related companies · 1

Companies working in the same space as Alkermes.

In the news

Frequently asked questions

What does Alkermes do?
Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders. The company leverages neuroscience expertise to create treatments for patients with complex conditions that are traditionally underserved.
Who are Alkermes's investors?
Alkermes's investors include Bain Capital Life Sciences, Cardinal Partners, Vedanta Capital, Hatteras Venture Partners.